Poplar Point Capital Partners Purchases 25,511 Shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Stock

Posted by Wayne Rhoads on Apr 16th, 2025

NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) major shareholder Poplar Point Capital Partners purchased 25,511 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $0.63 per share, for a total transaction of $16,071.93. Following the completion of the transaction, the insider now directly owns 808,277 shares of the company’s stock, valued at approximately $509,214.51. This trade represents a 3.26 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

On Friday, January 31st, Poplar Point Capital Partners acquired 70,685 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.65 per share, with a total value of $45,945.25.
On Monday, January 27th, Poplar Point Capital Partners bought 31,703 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.69 per share, for a total transaction of $21,875.07.
On Thursday, February 20th, Poplar Point Capital Partners purchased 1,836 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.63 per share, with a total value of $1,156.68.
On Tuesday, February 18th, Poplar Point Capital Partners acquired 3,222 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.66 per share, for a total transaction of $2,126.52.
On Monday, February 3rd, Poplar Point Capital Partners bought 2,597 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.64 per share, with a total value of $1,662.08.
On Friday, March 7th, Poplar Point Capital Partners purchased 102 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.55 per share, for a total transaction of $56.10.
On Tuesday, March 4th, Poplar Point Capital Partners acquired 4,000 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.58 per share, with a total value of $2,320.00.
On Thursday, February 27th, Poplar Point Capital Partners bought 385 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average price of $0.61 per share, for a total transaction of $234.85.
On Tuesday, February 25th, Poplar Point Capital Partners purchased 25,033 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.62 per share, for a total transaction of $15,520.46.
On Wednesday, March 12th, Poplar Point Capital Partners acquired 11,837 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.62 per share, with a total value of $7,338.94.

NovaBay Pharmaceuticals Stock Performance

NBY opened at $0.59 on Wednesday. The stock has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.01 and a beta of 0.90. The company has a fifty day moving average of $0.60 and a 200 day moving average of $0.63. NovaBay Pharmaceuticals, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $9.08.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on NovaBay Pharmaceuticals in a research note on Thursday, April 10th. They set a “hold” rating on the stock.

Check Out Our Latest Stock Report on NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Company Profile

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.